H.C. Wainwright Initiates Heat Biologics At Buy

H.C. Wainwright initiated coverage on

with a Buy rating. The target price for Heat Biologics is set to $13. Heat Biologics shares have gained 41.32 percent over the past 52 weeks, while the S&P 500 index has surged 11.87 percent in the same period. Heat Biologics' shares rose 3.04 percent to close at $6.43 on Friday.